Cognitive decline as a consequence of essential hypertension
- PMID: 21861834
- DOI: 10.2174/138161211798157685
Cognitive decline as a consequence of essential hypertension
Abstract
Hypertension is a leading cardiovascular risk for cardiovascular morbidity and mortality. Age is the strongest risk factor for dementia and with the increasing life expectancy the number of patients living with dementia worldwide is estimated to progressively rise. A number of studies support an association between hypertension, particularly in midlife, and the development of cognitive disorders and dementia, including Alzheimer's disease. According to this, considering hypertension as a possible modifiable risk factor for the cognitive decline is of great clinical interest. Treatment of hypertension in midlife seems to promote considerable benefits with regard to cardiovascular outcomes. Longitudinal studies examining the possible benefit of anti-hypertensive treatments on cognitive decline have produced promising results. Nevertheless, the results from randomised controlled clinical trials on treatment of hypertension are not conclusive for the effect on cognitive decline and dementia. New randomized controlled trials are needed to definitively clarify clinical advantages and specifically elucidate the relationship between anti-hypertensive treatments and cognitive function or dementia.
Similar articles
-
A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG) : An ongoing randomised, double-blind, placebo-controlled trial.Drugs Aging. 2006;23(1):83-92. doi: 10.2165/00002512-200623010-00008. Drugs Aging. 2006. PMID: 16492072 Clinical Trial.
-
[Cognitive functions and hypertension].Arch Mal Coeur Vaiss. 2005 Feb;98(2):133-9. Arch Mal Coeur Vaiss. 2005. PMID: 15787305 Review. French.
-
Treatment options and considerations for hypertensive patients to prevent dementia.Expert Opin Pharmacother. 2017 Jul;18(10):989-1000. doi: 10.1080/14656566.2017.1333599. Epub 2017 May 29. Expert Opin Pharmacother. 2017. PMID: 28532183 Review.
-
Hypertension, cognitive decline and dementia.Arch Cardiovasc Dis. 2008 Mar;101(3):181-9. doi: 10.1016/s1875-2136(08)71801-1. Arch Cardiovasc Dis. 2008. PMID: 18477946 Review.
-
The age-dependent relation of blood pressure to cognitive function and dementia.Lancet Neurol. 2005 Aug;4(8):487-99. doi: 10.1016/S1474-4422(05)70141-1. Lancet Neurol. 2005. PMID: 16033691 Review.
Cited by
-
Vascular risk factors and mild cognitive impairment in the elderly population in Southwest China.Am J Alzheimers Dis Other Demen. 2014 May;29(3):242-7. doi: 10.1177/1533317513517042. Epub 2013 Dec 27. Am J Alzheimers Dis Other Demen. 2014. PMID: 24375574 Free PMC article.
-
Antihypertensive and neuroprotective effects of catestatin in spontaneously hypertensive rats: interaction with GABAergic transmission in amygdala and brainstem.Neuroscience. 2014 Jun 13;270:48-57. doi: 10.1016/j.neuroscience.2014.04.001. Epub 2014 Apr 13. Neuroscience. 2014. PMID: 24731867 Free PMC article.
-
Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults.Nutr Healthy Aging. 2018 Jun 15;4(4):323-333. doi: 10.3233/NHA-170029. Nutr Healthy Aging. 2018. PMID: 29951592 Free PMC article.
-
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.Adv Drug Deliv Rev. 2012 May 15;64(7):629-39. doi: 10.1016/j.addr.2011.12.005. Epub 2011 Dec 17. Adv Drug Deliv Rev. 2012. PMID: 22202501 Free PMC article. Review.
-
Nanomedicine: A New Frontier in Alzheimer's Disease Drug Targeting.Cent Nerv Syst Agents Med Chem. 2025;25(1):3-19. doi: 10.2174/0118715249281331240325042642. Cent Nerv Syst Agents Med Chem. 2025. PMID: 38551038 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical